Lung Surfactants Market Regional Analysis by Growth Factor 2020-2025 | Chiesi Farmaceutici, AbbVie, NY Biotech, Lyomark Pharma, Windtree Therapeutics, Aviva Systems Biology Corporation

Lung Surfactants Market 2020 Global Industry research report studies latest Lung Surfactants industry aspects market size, share, trends, growth, business overview and Lung Surfactants industry scenario during the forecast period (2020-2025).

Global Lung Surfactants Market overview:

Surfactant is released from the lung cells and spreads across the tissue that surrounds alveoli. This substance lowers surface tension, which keeps the alveoli from collapsing after exhalation and makes breathing easy. The Global Lung Surfactants Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/280053 .

On the Basis of Product Type segment, the Lung Surfactants Market is sub segmented into Intratracheal and Injectable. Based on End Use Industry segment, the Lung Surfactants Market is segmented as Hospital, Special Clinic and Recovery Center.

There are several manufacturers of Lung Surfactants in Europe and North America. In North America, the demand for Lung Surfactants is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Lung Surfactants Market Report 2020” @ https://www.businessindustryreports.com/buy-now/280053/single .

Top Industry News:

AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ (upadacitinib) in Atopic Dermatitis on 19 October, 2020 -- AbbVie today announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for RINVOQ (upadacitinib) for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate to severe atopic dermatitis.

The atopic dermatitis indication applications to the FDA and EMA are supported by data from three pivotal Phase 3 studies. RINVOQ was studied without topical corticosteroids (TCS) in Measure Up 1 and Measure Up 2 and with TCS in AD Up. In all three studies, RINVOQ demonstrated significant improvement in skin clearance and reduction in itch in adults and adolescents with moderate to severe atopic dermatitis compared to placebo. RINVOQ met the co-primary endpoints including at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) from baseline and a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0/1 (clear or almost clear) at week 16. Additionally, more patients treated with either dose of upadacitinib experienced a clinically meaningful reduction in itch, defined as improvement in Worst Pruritus Numerical Rating Scale (NRS)≥4. The safety profile of RINVOQ was consistent across the three pivotal Phase 3 studies in atopic dermatitis. No new safety risks of RINVOQ were observed in these studies compared to the safety profile observed in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis receiving RINVOQ.

"While there have been advancements in care, patients with moderate to severe atopic dermatitis continue to experience relentless itch and skin symptoms that can impact their everyday lives," said Michael Severino, M.D., vice chairman and president, AbbVie. "These submissions are an important step forward in our commitment to providing an additional treatment option for those who struggle with this debilitating and often underappreciated disease."

Atopic dermatitis is characterized by a cycle of itching and scratching that leads to cracked, scaly, oozing skin, which intensifies with worsening disease severity. Between 20 to 46 percent of adults with atopic dermatitis have moderate to severe disease. The range of symptoms pose significant physical, psychological and economic burden on individuals impacted by the disease.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/280053 .

Major Key Players:

Some of the Lung Surfactants Market manufacturers involved in the market are Chiesi Farmaceutici, AbbVie, NY Biotech, Lyomark Pharma, Windtree Therapeutics, Aviva Systems Biology Corporation in World, effective mergers are some of the strategies adopted by the Lung Surfactants Market manufacturers. New product launches and continuous technological innovations are the Lung Surfactants Market strategies adopted by the major players.

Table of Contents:

1 Lung Surfactants Product Definition
2 Global Lung Surfactants Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Lung Surfactants Shipments
2.2 Global Manufacturer Lung Surfactants Business Revenue
2.3 Global Lung Surfactants Market Overview
3 Manufacturer Lung Surfactants Business Introduction
3.1 CHIESI FARMACEUTICI Lung Surfactants Business Introduction
3.1.1 CHIESI FARMACEUTICI Lung Surfactants Shipments, Price, Revenue and Gross profit 2020-2025
3.1.2 CHIESI FARMACEUTICI Lung Surfactants Business Distribution by Region
3.1.3 CHIESI FARMACEUTICI Interview Record
3.1.4 CHIESI FARMACEUTICI Lung Surfactants Business Profile
3.1.5 CHIESI FARMACEUTICI Lung Surfactants Product Specification
3.2 ABBVIE Lung Surfactants Business Introduction
3.2.1 ABBVIE Lung Surfactants Shipments, Price, Revenue and Gross profit 2020-2025
3.2.2 ABBVIE Lung Surfactants Business Distribution by Region
3.2.3 Interview Record
3.2.4 ABBVIE Lung Surfactants Business Overview
3.2.5 ABBVIE Lung Surfactants Product Specification
3.3 ONY BIOTECH Lung Surfactants Business Introduction
3.3.1 ONY BIOTECH Lung Surfactants Shipments, Price, Revenue and Gross profit 2020-2025
3.3.2 ONY BIOTECH Lung Surfactants Business Distribution by Region
3.3.3 Interview Record
3.3.4 ONY BIOTECH Lung Surfactants Business Overview
3.3.5 ONY BIOTECH Lung Surfactants Product Specification
3.4 Lyomark Pharma Lung Surfactants Business Introduction
3.5 Windtree Therapeutics Lung Surfactants Business Introduction
3.6 Aviva Systems Biology Corporation Lung Surfactants Business Introduction

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.